Drug modulation of microglia by Masters's team

This is from Florey Institue page telling one of Prof. Masters's interests and what relates to ATH and most likely to the license agreement Masters did with ATH.

Microglia are CNS-privileged innate immune cells deeply implicated in the etiology of Alzheimer’s disease (AD), frontal temporal dementia and Parkinson’s. They are responsible for rapid immune response to pathogens and molecular patterns of danger; changing their transcription profile to enact an aggressive phagoctyic response accompanied by massive oxidative bursts and release of pro-inflammatory cytokines. In AD, microglia become increasingly inefficient in their response to accumulating toxins in the AD brain and while stuck in a long-term dysregulated state contribute to neuronal loss in the decades between onset of pathology and dementia. Receptors that modulate their action are now the most targeted genes by the pharmaceutical industry in AD therapeutic development with potential applications in the treatment traumatic brain injury, schizophrenia, and Parkinsons’s disease.